Highwise Business
U.S.

Bactolife Launched Binding Protein Technology in US Market

The Denmark-based firm is targeting the practitioner-led supplement channel with its gut-stability proteins.

Updated on Sept. 30, 2026 in Healthcare

Isometric editorial illustration of a glass medical vial with white powder, set against a clean, flat-colored laboratory surface.
Bactolife has entered the United States market with its Helm Binding Protein technology, now being integrated into supplements distributed through healthcare practitioner channels. AI Illustration. Upload story photo >

Live Poll

Would you trust new lab-engineered protein supplements for your gut health over traditional probiotics?

Bactolife has officially introduced its Helm Binding Proteins to the United States, with partner Healthgevity integrating the technology into a gut-health supplement. The product launch follows the publication of safety data confirming the protein's profile for microbiome support.

Why it matters

The entry provides operators in the professional supplement space with a new functional ingredient designed for gut balance and barrier integrity. The technology aims to address growing consumer demand for targeted microbiome stability through a multi-mechanism approach.

Bactolife secured over €30 million, or approximately US$34 million, in Series B financing to scale its operations. The resulting Gutgevity supplement leverages six distinct mechanisms to support gut ecosystem stability.

The players

Bactolife

A Denmark-based biotechnology company that develops protein-based solutions for gut microbiome stability.

Healthgevity

A healthcare-focused firm that partners with practitioners to distribute specialized supplement products.

AceBiome

A biotech entity specializing in microbiome-based product development that maintains a partnership with Bactolife.

The details

The Helm Binding Proteins function by binding to and neutralizing specific compounds within the intestinal tract. This mechanism is intended to bolster gut barrier integrity and stabilize the microbiome, a step beyond traditional probiotic offerings. The technology is being deployed through Healthgevity’s distribution network, which focuses on the healthcare practitioner channel.

Timeline

  1. 2025: Safety and genotoxicity studies were published in the Journal of Applied Toxicology.

  2. January 2026: Bactolife completed a Series B funding round.

  3. Early 2026: The firm entered a development agreement with AceBiome.

  4. September 30, 2026: The US market launch was formally reported.

  5. October 28-30, 2026: The company will showcase its technology at SupplySide Global in Las Vegas.

Market Landscape

The introduction of Helm Binding Proteins follows the precedent set by safety validation published in the 2025 Journal of Applied Toxicology. This move aligns with a broader industry shift toward scientifically validated, non-probiotic interventions for gut health.

Operators in the practitioner channel should track the market adoption of multi-mechanism gut supplements as a potential substitute for traditional probiotic regimens. Assess whether this ingredient class fits into existing clinical protocols for patient gut stability.

The takeaway

The successful integration of binding proteins into the Gutgevity supplement signals a trend toward mechanism-specific gut health solutions. Practitioners and retailers should monitor the data presentation at the upcoming SupplySide Global trade show to evaluate the technology's clinical applicability.

What happens next

Bactolife will showcase its binding protein technology at the SupplySide Global trade show in Las Vegas, scheduled for October 28 to 30, 2026.

Further reading

For broader trends in the industry, visit the Healthcare section.

Live Poll

Would you trust new lab-engineered protein supplements for your gut health over traditional probiotics?